Search PubMed⌕ Search

Biomedical subjects

J Tanzer

Publications and source records attributed to J Tanzer.

At least 55 records · Page 3Linked to original sources
PubMed1991

Soluble CD23 displays T-cell growth enhancing activity.

Soluble CD23 (sCD23) enhances, in a dose-dependent manner, the number of secondary T-cell colonies generated by peripheral blood-derived agar T-colony cells in the presence of phytohaemagglutinin (PHA) and interleukin-2 (IL-2). This effect is not affected by IL-1 or IL-4 but is abolished by an anti-CD23 monoclonal antibody (mAb) or by IgE. No colonies were observed when sCD23 was added to PHA- or IL-2-free cultures. sCD23 also enhanced the cloning frequency of primary T-colony cells in a limiting dilution assay. These data provide the first direct evidence that sCD23 recruits T-cell clones in peripheral blood-born T cells and may be involved indirectly in the regulation of IgE response.

Antigens, Differentiation, B-Lymphocyte↗
PubMed1991

Chronic myelocytic leukaemia with unusual (27 years) complete remission terminating in acute undifferentiated leukaemia: a clinical and karyotypic study.

A case of clinically typical CML (300 x 10(6)/l leukocytes, 400 x 10(6)/l platelets, splenomegaly) is presented. After complete remission induced by busulphan, no clinical or haematological abnormalities were observed for 27 years until the development of acute leukaemia (type M1), which was rapidly fatal after a brief chemotherapy-induced remission. The cytogenetic findings were also original: no chromosome Ph1 (during remission 3 years after the onset of the disease), no translocation (banding study 5 years later), and no bcr/abl rearrangement (during the terminal phase).

Busulfan↗
PubMed1990

Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.

A new combination regimen including chemotherapy and interferon was started in 1986 for the treatment of 24 chronic myelogenous leukaemia patients in chronic phase. Complete cytogenetic remission were noted in 10 patients and 6 of them are in sustained remission. The overall survival was 70% at 40 months. However, a minimal residual disease was detected in the 3 patients tested with the polymerase chain reaction. In addition no correlation was detected between the site of the breakpoint and response to therapy.

Adult↗
PubMed1990

Two additional cases of t dic(9:12) in acute lymphocytic leukemia (ALL): prognosis in ALL with dic(9:12).

We report two occurrences of dic(9;12) in acute lymphoblastic leukemia and review previous cases. Cases of dic(9;12) share common features with cases of 9p and 12p rearrangements, but prognosis seems particularly good in cases of dic(9;12). The persistence of a specific dicentric in stable clones is remarkable and points to unusual centromeric behavior and/or marked selective advantage of the anomaly.

Adult↗
PubMed1989

Signal requirements for the generation of T-lymphocytes from T-depleted bone marrow cells: a sequential study.

We have investigated the sequence of signals provided by a B- and null-cell-derived prothymocyte-differentiating activity (PTDA), phytohemagglutinin (PHA), and interleukin 2 (IL2) to the generation of mature T-lymphocytes by T-depleted bone marrow (BM) cells. Sequential studies show that preincubation of CD2-, CD3-, CD4-, CD6-, and CD8- BM cells with PTDA, but not with recombinant (r) IL2 or PHA increased their capacity to proliferate in liquid culture and to form agar T-cell colonies provided both PHA and rIL2 were added to the cultures. In contrast, the growth of T-cell-containing BM was significantly enhanced in both liquid and agar culture following its preincubation with rIL2 as well as with PTDA. The selective effect of PTDA on CD2-, CD3-, CD4-, CD6-, CD8- BM cells was abolished by adding a CD7 monoclonal antibody to the T-cell-purging coctail. Cell marker studies performed on T-cell-depleted BM-derived liquid or agar cultures have shown that they contain up to 70%-85% CD2+, CD3+, CD4+, CD8- cells. No IL1 or IL2 could substitute for PTDA, nor have these activities, as well as interferon (IFN), IL3, IL4, or granulocyte-macrophage colony-stimulating activity (GM-CSA) been detected so far in PTDA-containing preparations. These results indicate that PTDA can trigger marrow T-cell precursors into PHA-responsive T cells, which, following activation by PHA, require IL2 for growth. It is suggested that this may represent a thymus-independent alternative pathway for T-cell differentiation and activation.

Antigens, CD7↗
PubMed1989

Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.

In view of the results achieved by others with interferons and also with low doses of Cytosine-arabinoside, we have treated 24 patients with IFN alpha 2a and Hydroxyurea for induction, with addition of low dose Ara-C during IFN maintenance therapy when the cytogenetic results were deemed insufficient. Complete hematological responses were obtained in 75% of the cases. Cytogenetic responses were noted in 83% of 12 previously untreated (complete or almost complete response in 3) and in 50% of previously treated patients (complete or almost complete response in 3 patients).

Adolescent↗
PubMed1989

Use of various mitogens and cell stimulation index in 21 patients with chronic lymphocytic leukaemia.

A number of mitogens was used in 21 chronic B-lymphocytic leukaemia patients. Thymidine uptake assays were performed to evaluate cell stimulation. Phytohemagglutinin and phorbol-myristate 13 acetate were found to be the most efficient on cell proliferation. Abnormal clones were found 7 times with PMA, 4 times with PHA, twice with pokeweed, but in no case with lipopolysaccharide or proteine-A. The efficiency of PHA as a B-cell activator is likely to be due to T cell mediation.

Adult↗
PubMed1989

Karyotypes of 33 patients with clonal aberrations in chronic lymphocytic leukaemia. Review of 216 abnormal karyotypes in chronic lymphocytic leukaemia.

We report on 33 unpublished patients with clonal anomalies in chronic lymphocytic leukaemia. The literature was thoroughly reviewed in order 1) to quantify the frequency of anomalies found in chronic lymphocytic leukaemia and to give new status to the rarest, 2) to determine whether a given anomaly was an additional anomaly and/or a primary anomaly, and 3) to find out whether strong associations between different anomalies exist in this disease.

Chromosome Aberrations↗
PubMed1988

The 8p11 anomaly in "monoblastic" leukaemia.

We report on three cases of monoblastic leukaemia with a chromosomal breakpoint at 8p11. One of our cases exhibited a translocation t(8;16) as has been described in 12 previous cases reported in 1987. The two other cases showed respectively t(6;8) and t(8;19) and they seem to be the first two reports of variant translocation in this disease. The available cases serve to define the main characteristics of this new subtype of non lymphocytic acute leukaemia: phagocytosis in most of the cases, the possible involvement of a granulomonocytic precursor, and a common breakpoint in 8p11.

Adult↗